KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Health Sciences and Medicine / 2026 / Volume: 7 Issue: 1

Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital

Aysun Taşdemir Arı(DR ERSIN ARSLAN EDUCATION AND RESEARCH HOSPİTAL)0009-0004-5412-5076
Mustafa Berhuni(DR ERSIN ARSLAN EDUCATION AND RESEARCH HOSPITAL)0000-0002-5725-2634
Gizem Gürbostan Soysal(DR ERSIN ARSLAN EDUCATION AND RESEARCH HOSPITAL)0000-0002-6314-9246
Nesime Setge Tıskaoğlu(DR ERSIN ARSLAN EDUCATION AND RESEARCH HOSPITAL)0000-0002-6441-788X
Sayfa
—
Yayın Tarihi
2024-01-15
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections.
📊
Temel Bulgular & Veri:Methods: Patients who received treatment with intravitreal bevacizumab (1.25 mg/0.05 ml) injections for various indications between November 2020 and March 2022 were included in this retrospective study.
💡
Sonuç & Katkı:It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.
🔬Tür:Research Article
📍Kapsam:2020 Verileri
⚙️Değişkenler:Bevacizumab · Intravitreal injections · Endophthalmitis

Abstract

Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections. Methods: Patients who received treatment with intravitreal bevacizumab (1.25 mg/0.05 ml) injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs. Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217%. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed. Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.

🔖

Bu Makaleye Atıf Yap

Arı, A. T., Berhuni, M., Soysal, G. G., Tıskaoğlu, N. S. (2024). Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital. Journal of Health Sciences and Medicine, Volume: 7 Issue: 1. https://doi.org/10.32322/jhsm.1367325

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (21)

  1. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.
  2. Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 2017;12(5):599-610.
  3. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):937-941.
  4. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond). 2010;24(5):816-824.
  5. Badalà F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-238.
  6. Seo JW, Park IW. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol. 2009;23(1):17-22.
  7. Zayek M, Parker K, Rydzewska M, Rifai A, Bhat R, Eyal F. Bevacizumab for retinopathy of prematurity: 2-year neurodevelopmental follow-up. Am J Perinatol. 2021;38(11):1158-1166.
  8. Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37(2):325-332.
  9. Ahmed N, Rehman HU, Rafique M, Hamza MS, Mirza HA. Incidence of acute endophthalmitis after intravitreal bevacizumab injection at a tertiary care hospital in Lahore. Cureus. 2021;13(2):e13185.
  10. Bro T, Derebecka M, Jørstad ØK, Grzybowski A. Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol. 2020;258(3):503-511.
  11. Durand ML. Endophthalmitis. Clin Microbiol Infect. 2013;19(3):227-234.
  12. Li T, Sun J, Min J, et al. Safety of receiving anti-vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: a meta-analysis. JAMA Ophthalmol. 2021;139(10):1080-1088.
  13. Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2009;23(12):2187-2193.
  14. Karimi S, Fakhri N, Ansari I, Hassanpour K, Safi S. Incidence and management of acute endophthalmitis after intravitreal injection of bevacizumab. Int Ophthalmol. 2022;42(6):1827-1833.
  15. Pradhan E, Duwal S, Bajimaya S, Thapa R, Sharma S, Manandhar A. Acute endophthalmitis after intravitreal bevacizumab injections at the tertiary centre in Nepal. Nepal J Ophthalmol. 2018;10(19):107-110.
  16. Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina. 2013;33(5):971-974.
  17. Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64(9):694-696.
  18. Hébert M, You E, Hammamji K, et al. Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections. Can J Ophthalmol. 2022;57(6):364-369.
  19. Bavinger JC, Yu Y, VanderBeek BL. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019;39(10):2004-2011.
  20. Tanaka K, Shimada H, Mori R, et al. Safety measures for maintaining low endophthalmitis rate after intravitreal anti-vascular endothelial growth factor injection before and during the COVID-19 pandemic. J Clin Med. 2022;11(3):876.
  21. Sousa DC, Jalil A, Patton N, et al. Early pars plana vitrectomy in acute endophthalmitis: The Manchester Series. Ophthalmic Surg Lasers Imaging Retina. 2022;53(2):96-102.